Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
46.23USD
22 Feb 2019
46.23USD
22 Feb 2019
Change (% chg)
$0.99 (+2.19%)
$0.99 (+2.19%)
Prev Close
$45.24
$45.24
Open
$45.23
$45.23
Day's High
$46.24
$46.24
Day's Low
$45.20
$45.20
Volume
100,574
100,574
Avg. Vol
98,223
98,223
52-wk High
$85.66
$85.66
52-wk Low
$36.10
$36.10
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 51.34 | 0.907 |
| Jun '18 | 59.30 | 0.172 | |
| Mar '18 | 46.63 | 0.169 | |
| FY 2017 | Dec '17 | 46.78 | 0.801 |
| Sep '17 | 63.02 | 0.979 | |
| Jun '17 | 50.11 | 0.280 | |
| Mar '17 | 76.79 | 1.418 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 3 | 55.60 | 58.70 | 52.90 | 55.40 |
| Quarter Ending Jun-19 | 3 | 59.10 | 62.50 | 56.40 | 57.00 |
| Year Ending Dec-19 | 5 | 231.63 | 250.54 | 218.60 | 223.93 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 2 | 1.05 | 1.16 | 0.94 | 1.19 |
| Quarter Ending Jun-19 | 2 | 1.17 | 1.20 | 1.15 | 1.02 |
| Year Ending Dec-19 | 5 | 4.39 | 5.45 | 3.74 | 4.36 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 9.78 | 30.48 | 33.70 | |
| P/E High - Last 5 Yrs. | -- | 44.98 | 49.87 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.25 | |
| Beta | 1.23 | 0.90 | 0.90 | |
| Price to Sales (TTM) | 3.59 | 4.12 | 6.29 | |
| Price to Book (MRQ) | 5.34 | 5.10 | 5.26 | |
| Price to Tangible Book (MRQ) | 9.43 | 5.85 | 6.77 | |
| Price to Cash Flow (TTM) | 8.87 | 24.01 | 24.98 | |
| % Owned Institutions | -- | 0.90 | 1.69 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.49 | 1.40 | |
| Dividend Yield - 5 Year Avg | -- | 1.51 | 1.42 | |
| Dividend 5 Year Growth Rate | -- | 4.15 | 4.85 | |
| Payout Ratio(TTM) | 0.00 | 43.91 | 41.03 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 22.46 | 4.31 | 12.76 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 160.39 | 4.07 | 5.84 | |
| Sales - 5 Yr. Growth Rate | -- | 10.91 | 11.23 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -64.84 | 44.94 | 47.15 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 3,637.76 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 10.31 | 10.85 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.88 | 15.20 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 3.76 | 2.15 | 2.25 |
| Current Ratio (MRQ) | 3.88 | 2.97 | 3.08 |
| LT Debt to Equity (MRQ) | 0.00 | 8.85 | 11.38 |
| Total Debt to Equity (MRQ) | 0.00 | 12.89 | 16.12 |
| Interest Coverage (TTM) | -- | 33.79 | 29.47 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 75.17 | 53.68 | 53.81 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.67 | 52.18 | |
| EBITD Margin (TTM) | 33.38 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 17.96 | 12.87 | |
| Operating Margin (TTM) | 32.21 | 14.31 | 6.19 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.24 | 8.31 | |
| Pre-Tax Margin (TTM) | 32.20 | 14.85 | 7.15 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.68 | 8.61 | |
| Net Profit Margin (TTM) | 39.32 | 11.08 | 3.29 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.02 | 4.89 | |
| Effective Tax Rate (TTM) | -22.12 | 23.02 | 22.91 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.16 | 23.38 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 3,193,182 | 957,633,237 | 842,390,177 | |
| Net Income/Employee (TTM) | 1,255,584 | 113,563,084 | 99,841,827 | |
| Receivable Turnover (TTM) | 4.67 | 5.71 | 5.71 | |
| Inventory Turnover (TTM) | 12.27 | 2.61 | 3.47 | |
| Asset Turnover (TTM) | 1.33 | 0.97 | 0.93 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 52.32 | 11.52 | 11.06 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.92 | 12.20 | |
| Return on Investment (TTM) | 64.07 | 14.95 | 14.45 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.84 | 15.87 | |
| Return on Equity (TTM) | 70.78 | 16.27 | 15.96 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.77 | 17.00 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 186.11 | -- | -- |
| EPS (TTM) % | 3,033.35 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eagle Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -1.54 | -4.93 | 29 | 22 |
| 13 Week | -28.91 | -32.37 | 9 | 39 |
| 26 Week | -33.14 | -38.22 | 12 | 33 |
| 52 Week | -9.55 | -23.34 | 38 | 9 |
| YTD | -26.58 | -35.52 | 17 | 26 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 93.88% |
| # of Holders: | 246 |
| Total Shares Held: | 14,000,247 |
| 3 Mo. Net Change: | -1,551,793 |
| # New Positions: | 27 |
| # Closed Positions: | 38 |
| # Increased Positions: | 112 |
| # Reduced Positions: | 110 |
| # Net Buyers: | 2 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.